AIMS AND BACKGROUND: Radiobiological and technical considerations have traditionally limited the role of radiation therapy in the context of primary and secondary cardiac malignancies. Stereotactic body radiotherapy (SBRT) is a promising modality for the delivery of focused high-dose radiation with ablative potential to complex targets such as small, deep-seated, moving lesions, allowing also for re-irradiation. METHODS: Between January 2013 and October 2013, 3 patients underwent SBRT for cardiac lesions: 2 patients had recurrent, previously irradiated cardiac angiosarcomas (PCA) and 1 patient had a cardiac metastasis from melanoma. They were treated with fiducial-guided robotic radiotherapy with CyberKnife. As for dose prescription, 24 Gy in 3 fractions (80% isodose) and 30 Gy in 5 fractions (80% isodose) were administered to the recurrent PCAs and cardiac metastasis, respectively. RESULTS: At 2 months after SBRT, cardiac MRI showed a partial response in the patients treated for recurrent PCA while the cardiac metastasis remained stable. In all cases, absence of local progression was subsequently confirmed by contrast-enhanced cardiac MRI after 6 months, without any evidence of treatment-related side effects. CONCLUSIONS: Fiducial-guided SBRT proved to be feasible and effective in preventing local disease progression in selected patients with cardiac malignancies.
AIMS AND BACKGROUND: Radiobiological and technical considerations have traditionally limited the role of radiation therapy in the context of primary and secondary cardiac malignancies. Stereotactic body radiotherapy (SBRT) is a promising modality for the delivery of focused high-dose radiation with ablative potential to complex targets such as small, deep-seated, moving lesions, allowing also for re-irradiation. METHODS: Between January 2013 and October 2013, 3 patients underwent SBRT for cardiac lesions: 2 patients had recurrent, previously irradiated cardiac angiosarcomas (PCA) and 1 patient had a cardiac metastasis from melanoma. They were treated with fiducial-guided robotic radiotherapy with CyberKnife. As for dose prescription, 24 Gy in 3 fractions (80% isodose) and 30 Gy in 5 fractions (80% isodose) were administered to the recurrent PCAs and cardiac metastasis, respectively. RESULTS: At 2 months after SBRT, cardiac MRI showed a partial response in the patients treated for recurrent PCA while the cardiac metastasis remained stable. In all cases, absence of local progression was subsequently confirmed by contrast-enhanced cardiac MRI after 6 months, without any evidence of treatment-related side effects. CONCLUSIONS: Fiducial-guided SBRT proved to be feasible and effective in preventing local disease progression in selected patients with cardiac malignancies.
Authors: Austin J Sim; Russell F Palm; Kirby B DeLozier; Vladimir Feygelman; Kujtim Latifi; Gage Redler; Iman R Washington; Evan J Wuthrick; Stephen A Rosenberg Journal: Clin Transl Radiat Oncol Date: 2020-10-31
Authors: Jose Duran-Moreno; Katerina Kampoli; Emmanouil I Kapetanakis; Maria Mademli; Nektarios Koufopoulos; Periklis G Foukas; Kostas Kostopanagiotou; Periklis Tomos; Anna Koumarianou Journal: In Vivo Date: 2019 Sep-Oct Impact factor: 2.155
Authors: Oliver Blanck; Svenja Ipsen; Mark K Chan; Ralf Bauer; Matthias Kerl; Peter Hunold; Volkmar Jacobi; Ralf Bruder; Achim Schweikard; Dirk Rades; Thomas J Vogl; Peter Kleine; Frank Bode; Jürgen Dunst Journal: Cureus Date: 2016-07-20
Authors: Stefanie Corradini; Rieke von Bestenbostel; Angela Romano; Adrian Curta; Dorit Di Gioia; Lorenzo Placidi; Maximilian Niyazi; Luca Boldrini Journal: Radiat Oncol Date: 2021-03-26 Impact factor: 3.481